Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
16 Maggio 2024 - 2:00PM
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage
biotechnology company whose proprietary INTASYL™ siRNA gene
silencing technology is designed to make immune cells more
effective in killing tumor cells, today announced it is presenting
data about its lead clinical candidate, PH-762, an INTASYL
compound. The data is being presented in three posters at the
annual meeting of the Society for Investigative Dermatology (SID)
this week in Dallas, Texas.
“We’re pleased to present the power of the INTASYL platform and
specifically, the applicability of lead compound PH-762 in treating
skin carcinomas, to this community dedicated to dermatological
research and patient care,” stated Linda Mahoney, Phio’s SVP of
Development.
PH-762 is an INTASYL compound that silences PD-1, a protein that
inhibits T cells' ability to kill cancer cells. In a murine model,
mPH-762 was well tolerated at the maximum administered dose and
treatment with mPH-762 provided robust inhibition of tumor growth.
Additionally, intratumoral mPH-762 treatment extended abscopal
efficacy to untreated distal tumors in bilateral models.
Toxicokinetic studies conducted in marmoset monkeys demonstrated
that PH-762, when administered intravenously is well-tolerated,
with no detectable cytokine-release associated cytokines found in
the plasma. The preclinical profile of PH-762 supports the ongoing
clinical development of the compound for the treatment of cutaneous
malignancies.
PH-762 is currently being studied in a US clinical trial to
assess safety and efficacy in specific skin cancers (NCT 06014086).
This open-label Phase 1b clinical study is designed to evaluate the
safety and tolerability of neoadjuvant use of intratumoral PH-762
in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4
melanoma, and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC
represent 77% of all new cSCC cases annually.
Presentation Details are as follows:
1. |
Title: |
INTASYL self-delivering RNAi: A Flexible Platform to Treat
Dermatological Malignancies |
|
Abstract Number: |
575 |
|
Session Title: |
Pharmacology and Therapeutic
Development |
|
Presenting Author: |
Melissa Maxwell |
|
Session Date/Time: |
Thursday, May 16,
4:30-6:30pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
2. |
Title: |
INTASYL PH-762: Intratumoral immunotherapy targeting PD-1 |
|
Abstract Number: |
576 |
|
Session Title: |
Pharmacology and Therapeutic
Development |
|
Presenting Author: |
Melissa Maxwell |
|
Session Date/Time: |
Friday, May 17, 4:00-6:00pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
3. |
Title: |
Intratumoral PH-762 targeting PD-1 for Cutaneous Carcinoma |
|
Abstract Number: |
283 |
|
Session Title: |
Clinical Research -
Interventional Research |
|
Presenting Author: |
Mary Spellman |
|
Session Date/Time: |
Thursday, May 16,
4:30-6:30pm |
|
Location: |
Trinity Exhibit Hall |
|
|
|
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ siRNA gene
silencing technology is designed to make immune cells more
effective in killing tumor cells. INTASYL is the only
self-delivering RNAi technology focused on immuno-oncology
therapeutics. INTASYL drugs precisely target specific proteins that
reduce the body’s ability to fight cancer, without the need for
specialized formulations or drug delivery systems.
For additional information, visit the Company’s website,
www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Examples of forward-looking statements
include statements regarding the potential of PH-762 to inhibit
tumor growth and extend abscopal efficacy to untreated distal
tumors. Our actual results may differ materially from those
indicated in the forward-looking statements as a result of a number
of important factors, including, but not limited to, the impact to
our business and operations by inflationary pressures, rising
interest rates, recession fears, the development of our product
candidates, results from our preclinical and clinical activities,
our ability to execute on business strategies, our ability to
develop our product candidates with collaboration partners, and the
success of any such collaborations, the timeline and duration for
advancing our product candidates into clinical development, the
timing or likelihood of regulatory filings and approvals, the
success of our efforts to commercialize our product candidates if
approved, our ability to manufacture and supply our product
candidates for clinical activities, and for commercial use if
approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact:Phio Pharmaceuticals
Corp.ir@phiopharma.com
PR ContactMichael AdamsBridge View
Mediaadams@bridgeviewmedia.com
Grafico Azioni Phio Pharmaceuticals (NASDAQ:PHIO)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Phio Pharmaceuticals (NASDAQ:PHIO)
Storico
Da Feb 2024 a Feb 2025